Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
Sign Up to like & getrecommendations! Published in 2017 at "Blood Cancer Journal"
DOI: 10.1038/bcj.2017.31
Abstract: Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide–dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib–lenalidomide–dexamethasone (KRd) was based on results from the randomized, phase… read more here.
Keywords: treatment; dexamethasone; carfilzomib; lenalidomide dexamethasone ... See more keywords